Inhibrx Statistics
Total Valuation
Inhibrx has a market cap or net worth of $1.62 billion. The enterprise value is $1.55 billion.
| Market Cap | 1.62B |
| Enterprise Value | 1.55B |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Inhibrx has 47.39 million shares outstanding. The number of shares has increased by 17.51% in one year.
| Shares Outstanding | 47.39M |
| Shares Change (YoY) | +17.51% |
| Shares Change (QoQ) | +14.76% |
| Owned by Insiders (%) | 19.57% |
| Owned by Institutions (%) | 86.55% |
| Float | 21.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 897.56 |
| Forward PS | 7,919.64 |
| PB Ratio | 37.14 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 859.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 4.83.
| Current Ratio | 5.25 |
| Quick Ratio | 4.95 |
| Debt / Equity | 4.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.58 |
Financial Efficiency
Return on equity (ROE) is -590.80% and return on invested capital (ROIC) is -86.43%.
| Return on Equity (ROE) | -590.80% |
| Return on Assets (ROA) | -84.10% |
| Return on Capital (ROIC) | -86.43% |
| Revenue Per Employee | $10,465 |
| Profits Per Employee | -$1.40M |
| Employee Count | 172 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Inhibrx has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.62% in the last 52 weeks. The beta is 2.92, so Inhibrx's price volatility has been higher than the market average.
| Beta (1Y) | 2.92 |
| 52-Week Price Change | +70.62% |
| 50-Day Moving Average | 35.64 |
| 200-Day Moving Average | 27.00 |
| Relative Strength Index (RSI) | 35.20 |
| Average Volume (30 Days) | 489,230 |
Short Selling Information
The latest short interest is 2.20 million, so 4.64% of the outstanding shares have been sold short.
| Short Interest | 2.20M |
| Short Previous Month | 2.15M |
| Short % of Shares Out | 4.64% |
| Short % of Float | 10.01% |
| Short Ratio (days to cover) | 4.60 |
Income Statement
In the last 12 months, Inhibrx had revenue of $1.80 million and -$241.36 million in losses. Loss per share was -$5.12.
| Revenue | 1.80M |
| Gross Profit | 1.80M |
| Operating Income | -219.22M |
| Pretax Income | -241.36M |
| Net Income | -241.36M |
| EBITDA | -206.56M |
| EBIT | -209.52M |
| Loss Per Share | -$5.12 |
Balance Sheet
The company has $277.92 million in cash and $210.14 million in debt, giving a net cash position of $67.78 million or $1.43 per share.
| Cash & Cash Equivalents | 277.92M |
| Total Debt | 210.14M |
| Net Cash | 67.78M |
| Net Cash Per Share | $1.43 |
| Equity / Book Value | 43.50M |
| Book Value Per Share | 0.92 |
| Working Capital | 239.05M |
Cash Flow
In the last 12 months, operating cash flow was -$193.31 million and capital expenditures -$4.59 million, giving a free cash flow of -$197.90 million.
| Operating Cash Flow | -193.31M |
| Capital Expenditures | -4.59M |
| Free Cash Flow | -197.90M |
| FCF Per Share | -$4.20 |
Margins
Gross margin is 100.00%, with operating and profit margins of -12,178.94% and -13,408.94%.
| Gross Margin | 100.00% |
| Operating Margin | -12,178.94% |
| Pretax Margin | -13,408.78% |
| Profit Margin | -13,408.94% |
| EBITDA Margin | -11,475.67% |
| EBIT Margin | -11,639.89% |
| FCF Margin | -10,994.56% |
Dividends & Yields
Inhibrx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.51% |
| Shareholder Yield | -17.51% |
| Earnings Yield | -14.94% |
| FCF Yield | -12.25% |
Analyst Forecast
The average price target for Inhibrx is $35.00, which is 2.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.00 |
| Price Target Difference | 2.67% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 202.70% |
| EPS Growth Forecast (5Y) | -18.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Inhibrx has an Altman Z-Score of -0.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 1 |